DOCSLIB.ORG

BARD1 and Associated Proteins and Its Application in Cancer Prognostics and Treatment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
BARD1 and Associated Proteins and Its Application in Cancer Prognostics and Treatment Functions of BARD1 and associated proteins and its application in cancer prognostics and treatment IrmgardIrmgard IrmingerIrminger--FingerFinger Biology of Aging Laboratory and Monitoring Laboratory University and University Hospitals of Geneva, Switzerland TumorTumor suppressorsuppressor BARD1BARD1 patented:patented: 1.Use as vaccine 2. Use for cell killing 3.Use as prognostic marker IrmgardIrmgard IrmingerIrminger--FingerFinger University and University Hospitals Geneva Clinical application of BARD1: background and principles The “normal” functions of BARD1 BARD1 expression in tumors: in breast and ovarian cancers in lung cancer BARD1 expression the human cytotrophoblast: a non-malignant cells with an invasive phenotype AND in amnion fluid-secreted by the cytotrophoblast? Detection of BARD1 in serum for cancer screening? Immunogenic BARD1 applied for tumor cell killing Genes implicated in epithelial cancers: predisposition genes (tumor suppressor genes) • p53 (lung, colon, breast, prostate) • BRCA1 (breast, ovary, prostate) • BRCA2 (breast, ovary) • BARD1 (breast, ovary, uterus, – and other proliferative tissues) Function: repair, apoptosis (cell death) Old Age Cancers are derived from epithelial cells BCC Basal cell carcinoma SCC Squamous cell carcinoma DePinho, 2000 Accumulation of damage during aging agingaging damaged cells long-term loss of abnormal function functional tissue abnormal activation (Alzheimer, heart abnormal growth failure etc.) apoptosis cancer environmental insult damage BARD1 Accumulation decision of endogenous BARD1 making damage repairrepair BARD1 and its interacting proteins:a converging vehicle Rad51 PCNA ? RNA-Pol II p53 BAP1 BACH1 RHA BRCA2 Ankyrin BARD1- BRCA1 RING repeats Phospho-binding BRCT interaction domain Transcription Ubiquitin-ligase Polyadenylation activity P53 activation NFk-B binding DNA-PK apoptosis Irminger-Finger et al., Bioch. 1999; Irminger-Finger et al., Mol Cell 2001; Feki et al. & Irminger-Finger, BOR 2005 BARD1 and BRCA1 mutations predisposing to breast cancer A1009T A1481G G1743C A957G 1144del21 G1592A G1765C Q513H 358D364 C557S K312N N295S Human BARD1 RING ANK BRCT RING BRCT Human BRCA1 C>G Missense mutations Y>A No one like BARD1 RING ANK BRCT BARD1 BRCA1 Arabidopsis 2 hypoth.p. Arabidopsis CAC05430 C. elegans 3 hypoth. p. C. elegans 6 hypoth. p. C. elegans T15564 C. elegans T15566 Xenopus BARD1 Joukov, Livingston, PNAS, 2001 BRCA1 Irminger-Finger and Leung, IJBCB 2002 BARD1 induces apoptosis in a p53-mediated pathway BARD1 binds to p53 A non-treat. doxo IP: α -p53 S P S P transfection of BARD1 BARD1 p53+/+ p53-/- PCNA non-treat. doxo IP: α -BARD1 S P S P p53 PCNA BARD1 stabilizes p53 B pcBARD1 pcBQ>H IP: α-BARD1 S P S P p53 BARD1 Irminger-Finger et al., Mol Cell 2001 Mapping of the apoptotic region 3 1 T G A C K N D N 2 R R N G I K C557S Q564H D N R c A B A I N p B ∆ ∆ R ∆ A RING ANKYRIN BRCT BARD1 APO NLS131 NLS 408 NLS 693 BARD1 yes ∆ RING yes ∆ BRCT yes ANK2 yes RING no ∆ ANK yes X no BARD1 Q564H ? Deletion mutants lacking the BRCA1 interaction domain are efficient in apoptosis induction and have increased protein stability BARD1 is upregulated in response to cellular stress On the protein level On the mRNA level TAC-2 cells ES cells Doxorubicin UV - 1 4 - min doxo -- -10 µg BARD1 p53 Western RT-PCR Mechanism of apoptosis induction by BARD1 • Exogenous expression of BARD1 leads to apoptosis • BARD1-induced apoptosis depends on functional p53 • Upregulation of BARD1 results in stabilization of p53 protein • Repression/deletion of BARD1 results in apoptosis resistence BARD1 deficient tumor cells: NuTu-19 resistent to apoptosis A H-300 PVC JH3 9 9 9 -1 -1 -1 u u u C T T T T T T 93 u 93 u 93 u 2 N 2 N 2 N H-300 PVC JH-3 BARD1 BARD1 RING ANK BRCT In In In In B In In In 5 6 7 8 In In 2 3 4 9 1 M p53 BARD1 2KB BARD1 In In In In In In In 5 6 7 8 In In 2 3 4 9 1 2.2 kb 0.8KB BARD1 2 kb 0.8 kb Feki et al., & Irminger-Finger, Oncogene 2005 BARD1 required for p53 phosphorylation Apoptotic treatment BARD1 transfection TAC2 NuTu-19 HEK NuTu-19 doxo - + -+ BARD1 - + -+ BARD BARD1 1 C p53 p53 p-p53 p-p53 actin actin Exogenous expression of BARD1 can induce apoptosis in NuTu-19 cells 50 45 NuTu-19 40 TAC2 35 is 30 25 20 of apoptos 15 % 10 5 0 NuTu-19 NuTu-19 NuTu-19 TAC-2 TAC-2 + Doxo + BARD1 + Doxo BARD1 colocalizes with phospho-p53 A DAPI FITC P53-Alexa 555 MERGE DAPI FITC Phospho-p53-Alexa 555 MERGE Mapping p53 binding region IP p53 BARD1 ∆-RING ∆-HIND ∆-BRCT ANK RING EGFP SP SP SP SP SP SP SP 1144del2 G1592A G2354A A1481G A1009T1 G1743C G215C A957G G176C RING ANK BRCT mBARD1 p53 NLS 131 NLS 408 NLS 693 binding apo BARD1 (aa 1-765) EGFP 100 yes ∆ RING (aa 137-765) EGFP 60 yes ∆ HIND (aa 394-765) EGFP 80 yes ∆ BRCT (aa 1-604) EGFP 100 yes ANK (aa 394-604) EGFP 60 yes RING (aa 1-266) EGFP 0 no Feki et al., and Irminger-Finger, Oncogene 2005 BARD1 induces apoptosis by catalyzing phosphorylation of p53 • BARD1 binds to p53 and to phosphorylated p53 • BARD1 binds to Ku-70, the catalytic subunit of DNA-PK but not ATM • Exogenous expression of BARD1 in BARD1- deficient cells induces p53 phosphorylation • Exogenous expression of BARD1 in BARD1 deficient cells restores apoptosis sensitivity Co-localization of BRCA1 and BARD1 with repair proteins in “nuclear dots” +BARD1 +BARD1 Jin, Baer, JBC 1997; Scully, Livingston, Cell 1997 ....but not only “nuclear dots” pEGFP BARD1-EGFP ∆RING- A EGFP ∆BRCT-EGFP ANK-EGFP RING-EGFP s l 60 B cel 50 40 GFP+ c RING-EGFP30 20 optoti p a 10 % 0 EGFP- BARD1- RING- ∆-RING- ∆-HIND - ∆-BRCT ANK- N1 EGFP EGFP EGFP EGFP EGFP EGFP BARD1 translocates to the cytoplasm during apoptosis T=6 T=12 T=24 T=48 Jefford et al., & Irminger-Finger, Oncogene 2004 Intracellular localization of BARD1 upon apoptosis induction non treated UV BARD1 BRCA1 BARD1 is translocated to the cytoplasm during apoptosis Total cell extract Nucl. extract Cytopl. extract 0 3 4 5 6 7 14 22 24 h 0 3 4 5 6 7 14 22 24 h 0 3 4 5 6 7 14 22 24 h ** * p67 Ab: PVC Ab: C20 Ab: C20 The C-terminal p67 is translocated to the cytoplasm and is immunogenic and anti-tumorigenec in an animal model of colon cancer (Gautier, Irminger-Finger et al., Cancer Res 2000). Apoptotic function of BARD1 in vivo • In morphogenesis spermatogenesis •In homeostasis Spleen, bone • In tumor suppression Cytoplasmic localization of BARD1 in vivo A BARD1 PVC BARD1 N-19 B BARD1 N-19 BARD1 upregulation in vivo by ischemia Left hemisphere Penumbra Core region Left hemisphere BRCA1 BRCA1 BARD1 Apoptosis and (meiotic) repair during spermatogenesis Bcl-x PMB4 SCF IL-4 LIF SCF Gas6 LIF Bcl-xL Bcl-xL bFGF TGFß CNTF testosterone Bax testosterone Bax - + - --+ - + Spermatogonia Spermatocytes Spermatids Spermatozoa PGC Gonocytes Apoptosis Apoptosis Apoptosis Apoptosis BARD1? Modified from: Print, Bioassays, 2000 Schematic diagram of seminiferous tube BARD1 expression is correlated with apoptosis markers A anti-BARD1 a a TUNEL b b Feki et al., & Irminger-Finger, BOR 2004 B activated caspase 3 anti-BARD1 N-19 a b a b c d N-19 c d f JH3 e f e BARD1 and BRCA1 expression overlap partially a b A BARD1 a b 5x 20x 20x B c d d BRCA1 c 5x 40x 40x C 5x Different BARD1 isoforms are expressed at different stages A GPLPjr P SR 97 kD 74 kD C-20 Western blot 97 kD JH-3 74 kD 97 kD JH-2 74 kD B GPLPjr P SR 2300 bp RT-PCR 2000 bp BARD1 GAPDH BARD1β lacks the RING finger N-19 PVC JH-2 JH-3 C-20 Q>H BARD1 RING ANK BRCT In In5 6 In7 In8 In In2 In3 In4 9 In1 BARD1β BARD1β is an efficient apoptosis inducer 100 90 80 70 eath 60 d 50 cell 40 % 30 20 10 0 CGR8 BARD1b BARD1b BARD1 BARD1 Doxo BRCA1 BRCA1 p53 CGR8 BARD1b BARD1b BARD1 BARD1 Doxo BRCA1 BRCA1 BARD1 expression associated with abortive spermatogenesis A Obstructive Azoospermia Sertoli cell Syndrome cryptorchidy B c d 3 2 1 Presumed tumor suppressor pathways of BARD1 6 Cleavage immunogenic or isoform of BARD1 4 3 p53 5 BARD1 1 ARD1 p53 BARD B apoptosis p53 2 p53 BARD1 BARD1 Other p53 stabilizing signals? BARD1 1 DNA repair pathways BRCA1 (e.g.ubiquitination) Cell cycle arrest BRCA1 BARD1 Irminger-Finger et al., Mol Cell 2001 Expected loss of BARD1 in tumorigenesis Carcinogenic stress transcription activation Pser15 apoptosis BARD1 p53 -loss of BARD1 -loss of p53 BRCA1 p53 turnover mutated or deleted - inhibition of degradation Carcinogenesis - direct stabilization However, BARD1 is upregulated in tumors a N19 5x b a b N19 40x N19 40x BARD1 expression is specific for tumor type N19 C20 A C C C 5x 5x C n E 5x 5x C e S 5x 5x uC M 5x 5x Expression of N- and C-terminal epitopes N19 C20 N19 C20 5x 5x 5x 5x 40x 40x 40x 40x 100 OB18 OB41 OB42 OB15 90 OB16 OB44 OB43 OB11 80 OB35 OB12 OB38 OB39 70 OB40 OB14 OB13 OB36 OB37 OB31 60 OB33 OB29 OB34 OB30 50 OB32 OB2 OB3 OB4 19 positive cells 40 OB9 OB17 N OB23 OB28 OB24 OB25 30 OB5 OB27 OB22 OB26 % of 20 OB21 OB10 OB19 OB20 10 OB1 OB6 0 OB7 OB8 CCC EnC SeC MuC Correlation of BARD1 expression with tumor grade OB16 A1 Clair cell carcinoma C20 x40 BARD1 but not p53 is correlated with tumor type A N19 p53 B Correlation of BARD1 and p53 with histological type of ovarian carcinoma 100 90 N19 C20 80 p53 40x 40x 70 60 50 40 positive cells 30 20 % of 10 40x 40x 0 CCCEnC SeCMuC Figure 3 Correlation of BARD1 expression with tumor grade and stage Correlation of BARD1 and p53 with differentiation in Correlation of BARD1 and p53 with tumor size in sporadic breast cancer sporadic breast cancer D 35 70 N19 N19 60 30 C20 C20 p53 s p53 25 l 50 s l l l e e c c 20 40 e e v i v t i 15 30 i t i s s o o 10 20 p p f f o o 5 10 % % 0 0 G1 G2 G3 T1 T2 T3 T4 No correlation of BARD1 and p53 expression
Load more

Recommended publications
  • Loss of BCL-3 Sensitises Colorectal Cancer Cells to DNA Damage, Revealing A
    bioRxiv preprint doi: https://doi.org/10.1101/2021.08.03.454995; this version posted August 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title: Loss of BCL-3 sensitises colorectal cancer cells to DNA damage, revealing a role for BCL-3 in double strand break repair by homologous recombination Authors: Christopher Parker*1, Adam C Chambers*1, Dustin Flanagan2, Tracey J Collard1, Greg Ngo3, Duncan M Baird3, Penny Timms1, Rhys G Morgan4, Owen Sansom2 and Ann C Williams1. *Joint first authors. Author affiliations: 1. Colorectal Tumour Biology Group, School of Cellular and Molecular Medicine, Faculty of Life Sciences, Biomedical Sciences Building, University Walk, University of Bristol, Bristol, BS8 1TD, UK 2. Cancer Research UK Beatson Institute, Garscube Estate, Switchback Road, Bearsden Glasgow, G61 1BD UK 3. Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, CF14 4XN UK 4. School of Life Sciences, University of Sussex, Sussex House, Falmer, Brighton, BN1 9RH UK 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.08.03.454995; this version posted August 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract (250 words) Objective: The proto-oncogene BCL-3 is upregulated in a subset of colorectal cancers (CRC) and increased expression of the gene correlates with poor patient prognosis. The aim is to investigate whether inhibiting BCL-3 can increase the response to DNA damage in CRC.
    [Show full text]
  • Identification and Characterization of Missense Alterations in the BRCA1
    633 ORIGINAL ARTICLE Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer M K Sauer, I L Andrulis ............................................................................................................................... J Med Genet 2005;42:633–638. doi: 10.1136/jmg.2004.030049 Background: BRCA1 associated RING domain protein (BARD1) was originally identified due to its interaction with the RING domain of BRCA1. BARD1 is required for S phase progression, contact inhibition and normal nuclear division, as well as for BRCA1 independent, p53 dependent apoptosis. See end of article for Methods: To investigate whether alterations in BARD1 are involved in human breast and ovarian cancer, authors’ affiliations ....................... we used single strand conformation polymorphism analysis and sequencing on 35 breast tumours and cancer cell lines and on 21 ovarian tumours. Correspondence to: Results: Along with the G2355C (S761N) missense mutation previously identified in a uterine cancer, we Dr M K Sauer, Samuel Lunenfeld Research found two other variants in breast cancers, T2006C (C645R) and A2286G (I738V). The T2006C (C645R) Institute, Mount Sinai mutation was also found in one ovarian tumour. A variant of uncertain consequence, G1743C (C557S), Hospital, 600 University was found to be homozygous or hemizygous in an ovarian tumour. Eleven variants of BARD1 were Ave, Toronto, Ontario, M5G 1X5, Canada; characterised with respect to known functions of BARD1. None of the variants appears to affect [email protected] localisation or interaction with BRCA1; however, putative disease associated alleles appear to affect the stability of p53. These same mutations also appear to abrogate the growth suppressive and apoptotic Received activities of BARD1.
    [Show full text]
  • Functional Characterization of Full-Length BARD1 Strengthens Its
    Journal of Cancer 2020, Vol. 11 1495 Ivyspring International Publisher Journal of Cancer 2020; 11(6): 1495-1504. doi: 10.7150/jca.36164 Research Paper Functional characterization of full-length BARD1 strengthens its role as a tumor suppressor in neuroblastoma Flora Cimmino1,2, Marianna Avitabile1,2, Vito Alessandro Lasorsa1,2, Lucia Pezone1, Antonella Cardinale1, Annalaura Montella2, Sueva Cantalupo3, Achille Iolascon1,2, Mario Capasso1,2,3 1. Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli “Federico II”, Naples, Italy 2. CEINGE Biotecnologie Avanzate, Naples, Italy 3. IRCCS SDN, Naples, Italy Corresponding author: Flora Cimmino, phD, University of Naples Federico II, Department of Molecular Medicine and Medical Biotechnology, CEINGE Biotecnologie Avanzate, Via Gaetano Salvatore, 486, 80145 Napoli Italy. Lab: +39 0813737736; Fax: +39 0813737804; Email: [email protected] © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions. Received: 2019.04.29; Accepted: 2019.11.12; Published: 2020.01.14 Abstract BARD1 is associated with the development of high-risk neuroblastoma patients. Particularly, the expression of full length (FL) isoform, FL BARD1, correlates to high-risk neuroblastoma development and its inhibition is sufficient to induce neuroblastoma cells towards a worst phenotype. Here we have investigated the mechanisms of FL BARD1 in neuroblastoma cell lines depleted for FL BARD1 expression. We have shown that FL BARD1 expression protects the cells from spontaneous DNA damage and from damage accumulated after irradiation. We demonstrated a role for FL BARD1 as tumor suppressor to prevent unscheduled mitotic entry of DNA damaged cells and to lead to death cells that have bypassed cell cycle checkpoints.
    [Show full text]
  • BRCA1–BARD1 Regulates Axon Regeneration in Concert with the Gqα–DAG Signaling Network
    Research Articles: Cellular/Molecular BRCA1–BARD1 regulates axon regeneration in concert with the Gqα–DAG signaling network https://doi.org/10.1523/JNEUROSCI.1806-20.2021 Cite as: J. Neurosci 2021; 10.1523/JNEUROSCI.1806-20.2021 Received: 13 July 2020 Revised: 20 January 2021 Accepted: 5 February 2021 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.jneurosci.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2021 Sakai et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. Sakai et al., 1 1 BRCA1–BARD1 regulates axon regeneration in 2 concert with the GqD–DAG signaling network 3 4 Abbreviated Title: BRCA1–BARD1 regulates axon regeneration 5 6 Yoshiki Sakai, Hiroshi Hanafusa, Tatsuhiro Shimizu, Strahil Iv. 7 Pastuhov, Naoki Hisamoto, and Kunihiro Matsumoto 8 9 Division of Biological Science, Graduate School of Science, Nagoya University, 10 Chikusa-ku, Nagoya 464-8602, Japan 11 12 To whom correspondence should be addressed: 13 Kunihiro Matsumoto and Naoki Hisamoto 14 Division of Biological Science, Graduate School of Science, 15 Nagoya University, Chikusa-ku, Nagoya 464-8602, Japan. 16 E-mail address: [email protected] (K.
    [Show full text]
  • BARD1 in Cell Life and Death
    Role of BARD1 in cell life and death Irmgard Irminger-Finger Biology of Aging Laboratory Department of Geriatrics University of Geneva Switzerland Age is the biggest risk factor for cancer DePinho, 2000 Cancer Risks for Men prostate From1950 1990 Cancer Risks for Women breast From1950 1990 Cancers of old age are different from young age cancers Cancer in old age has a different face than cancer in young age BCC Basal cell carcinoma SCC Squamous cell carcinoma DePinho, 2000 What could link epithelial cell derived cancers to aging? BARD1, not just another cancer predisposition gene Common pathways for cancer and aging? Accumulation of damage DNA damage DNA damage proliferation- DNA damage arrest repair senescence proliferation cancer elimination apoptosis Cellular aging BARD1 Summary • BARD1 structure • BARD1 repression studies • BARD1 overexpression studies • BARD1 dynamic localization • BARD1 induced upon stress • Non-correlated expression of BARD1 and BRCA1 • Role in spermatogenesis • BARD1 upregulation upon stress • Role in tumorigenesis • BARD1 a tumor antigen • BARD1 in cancer vaccine and genetherapy Conserved structures in BARD1 and BRCA1 Q>H RING ANK BRCT BARD1 66 95 53 97 77 91 conservation RING BRCT BRCA1 C>G No one like BARD1 RING ANK BRCT BARD1 BRCA1 Arabidopsis 2 hypoth.p. Arabidopsis CAC05430 C. elegans 3 hypoth. p. C. elegans 6 hypoth. p. C. elegans T15564 C. elegans T15566 Xenopus BARD1 Joukov, Livingston, PNAS, 2001 BRCA1 BARD1- BRCA1 heterodimer Rad51 PCNA ? RNA-Pol II p53 BAP1 Nuclear localization BACH1 RHA signals Granin BRCA2 motif BARD1 interaction Ankyrin repeats BRCT BRCA1 domain interaction Ubiquitin-ligase Polyadenylation activity A B C D BARD1 BRCA1 BARD1 BRCA1 BARD1 Bcl-3 Pol II/Holo CstF-50 NF-kB Replication? S-phase dots Transcription: mRNA Regulation of Pol II/Holo Interaction Processing? transcription? [Scully et al.
    [Show full text]
  • Hyaluronan Mediated Motility Receptor (HMMR) Encodes an Evolutionarily Conserved Homeostasis, Mitosis, and Meiosis Regulator Rather Than a Hyaluronan Receptor
    cells Review Hyaluronan Mediated Motility Receptor (HMMR) Encodes an Evolutionarily Conserved Homeostasis, Mitosis, and Meiosis Regulator Rather than a Hyaluronan Receptor 1 1 1, 1,2, Zhengcheng He , Lin Mei , Marisa Connell y and Christopher A. Maxwell * 1 Department of Pediatrics, University of British Columbia, Vancouver, BC V5Z 4H4, Canada; [email protected] (Z.H.); [email protected] (L.M.); [email protected] (M.C.) 2 Michael Cuccione Childhood Cancer Research Program, BC Children’s Hospital, Vancouver, BC V5Z 4H4, Canada * Correspondence: [email protected]; Tel.: +1-6048752000 (ext. 4691) Current position: Department of Neuroscience and Physiology, SUNY Upstate Medical University, Syracuse, y NY 13210, USA. Received: 3 March 2020; Accepted: 25 March 2020; Published: 28 March 2020 Abstract: Hyaluronan is an extracellular matrix component that absorbs water in tissues and engages cell surface receptors, like Cluster of Differentiation 44 (CD44), to promote cellular growth and movement. Consequently, CD44 demarks stem cells in normal tissues and tumor-initiating cells isolated from neoplastic tissues. Hyaluronan mediated motility receptor (HMMR, also known as RHAMM) is another one of few defined hyaluronan receptors. HMMR is also associated with neoplastic processes and its role in cancer progression is often attributed to hyaluronan-mediated signaling. But, HMMR is an intracellular, microtubule-associated, spindle assembly factor that localizes protein complexes to augment the activities of mitotic kinases, like polo-like kinase 1 and Aurora kinase A, and control dynein and kinesin motor activities. Expression of HMMR is elevated in cells prior to and during mitosis and tissues with detectable HMMR expression tend to be highly proliferative, including neoplastic tissues.
    [Show full text]
  • Isomerization of BRCA1-BARD1 Promotes Replication Fork Protection
    University of Birmingham Isomerization of BRCA1-BARD1 promotes replication fork protection Daza-Martin, Manuel; Starowicz, Katarzyna; Jamshad, Mohammed; Tye, Stephanie; Ronson, George E; MacKay, Hannah L; Chauhan, Anoop Singh; Walker, Alexandra K; Stone, Helen R; Beesley, James F J; Coles, Jennifer L; Garvin, Alexander J; Stewart, Grant S; McCorvie, Thomas J; Zhang, Xiaodong; Densham, Ruth M; Morris, Joanna R DOI: 10.1038/s41586-019-1363-4 License: None: All rights reserved Document Version Peer reviewed version Citation for published version (Harvard): Daza-Martin, M, Starowicz, K, Jamshad, M, Tye, S, Ronson, GE, MacKay, HL, Chauhan, AS, Walker, AK, Stone, HR, Beesley, JFJ, Coles, JL, Garvin, AJ, Stewart, GS, McCorvie, TJ, Zhang, X, Densham, RM & Morris, JR 2019, 'Isomerization of BRCA1-BARD1 promotes replication fork protection', Nature, vol. 571, no. 7766, pp. 521-527. https://doi.org/10.1038/s41586-019-1363-4 Link to publication on Research at Birmingham portal Publisher Rights Statement: Checked for eligibility: 11/07/2019 https://www.nature.com/articles/s41586-019-1363-4 Daza-Martin, Manuel, et al. "Isomerization of BRCA1–BARD1 promotes replication fork protection." Nature (2019): 1. https://doi.org/10.1038/s41586-019-1363-4 General rights Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law. •Users may freely distribute the URL that is used to identify this publication. •Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
    [Show full text]
  • BRCC3 Acts As a Prognostic Marker in Nasopharyngeal
    Tu et al. Radiation Oncology (2015) 10:123 DOI 10.1186/s13014-015-0427-3 RESEARCH Open Access BRCC3 acts as a prognostic marker in nasopharyngeal carcinoma patients treated with radiotherapy and mediates radiation resistance in vitro Ziwei Tu1,2, Bingqing Xu1,2, Chen Qu1,2, Yalan Tao1,2, Chen Chen1,2, Wenfeng Hua2, Guokai Feng2, Hui Chang1, Zhigang Liu3, Guo Li4, Changbin Jiang5, Wei Yi5, Musheng Zeng2 and Yunfei Xia1,2* Abstract Background: BRCC3 has been found to be aberrantly expressed in breast tumors and involved in DNA damage response. The contribution of BRCC3 to nasopharyngeal carcinoma prognosis and radiosensitivity is still unclear. Methods: Immunohistochemical analysis of BRCC3 was carried out in 100 nasopharyngeal carcinoma tissues, and the protein level was correlated to patient survival. BRCC3 expression of nasopharyngeal carcinoma cell lines was determined by Western-blotting and real-time PCR. Additionally, the effects of BRCC3 knockdown on nasopharyngeal carcinoma cell clongenic survival, DNA damage repair, and cell cycle distribution after irradiation was assessed. Results: The BRCC3 protein level was inversely correlated with nasopharyngeal carcinoma patient overall survival (P < 0.001) and 3-year loco-regional relapse-free survival (P = 0.034). Multivariate analysis demonstrated that BRCC3 expression was an independent prognostic factor (P = 0.010). The expression of BRCC3 was much higher in radioresistant nasopharyngeal carcinoma cells than in radiosensitive cells. Knockdown of BRCC3 increased the cell survival fraction, attenuated DNA damage repair and resulted in G2/M cell cycle arrest in radioresistant NPC cells. Conclusions: High BRCC3 expression in nasopharyngeal carcinoma patients is associated with poor survival.
    [Show full text]
  • Literature Review of BARD1 As a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers
    G C A T T A C G G C A T genes Review Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers 1,2,3, 1,2, 1,2 1,2,4, Wejdan M. Alenezi y , Caitlin T. Fierheller y, Neil Recio and Patricia N. Tonin * 1 Department of Human Genetics, McGill University, Montreal, QC H3A 0G4, Canada; [email protected] (W.M.A.); caitlin.fi[email protected] (C.T.F.); [email protected] (N.R.) 2 Cancer Research Program, The Research Institute of the McGill University Health Centre, Montreal, QC H4A 3J1, Canada 3 Department of Medical Laboratory Technology, Taibah University, Medina 42353, Saudi Arabia 4 Department of Medicine, McGill University, Montreal, QC H3A 0G4, Canada * Correspondence: [email protected]; Tel.: +1-514-934-1934 (ext. 44069) Contributed equally to the work. y Received: 30 June 2020; Accepted: 23 July 2020; Published: 27 July 2020 Abstract: Soon after the discovery of BRCA1 and BRCA2 over 20 years ago, it became apparent that not all hereditary breast and/or ovarian cancer syndrome families were explained by germline variants in these cancer predisposing genes, suggesting that other such genes have yet to be discovered. BRCA1-associated ring domain (BARD1), a direct interacting partner of BRCA1, was one of the earliest candidates investigated. Sequencing analyses revealed that potentially pathogenic BARD1 variants likely conferred a low–moderate risk to hereditary breast cancer, but this association is inconsistent. Here, we review studies of BARD1 as a cancer predisposing gene and illustrate the challenge of discovering additional cancer risk genes for hereditary breast and/or ovarian cancer.
    [Show full text]
  • Fusion Protein EWS-FLI1 Is Incorporated Into a Protein Granule in Cells
    Downloaded from rnajournal.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press Fusion protein EWS-FLI1 is incorporated into a protein granule in cells Nasiha S. Ahmed1,2, Lucas M. Harrell2, Daniel R. Wieland2, Michelle A. Lay2, Valery F. Thompson2, Jacob C. Schwartz2* 1 Department of Molecular and Cellular Biology, The University of Arizona, Tucson, AZ 85719 2 Department of Chemistry and Biochemistry, The University of Arizona, Tucson, AZ 85719 * Corresponding author: [email protected] Keywords: Ewing sarcoma, fusion proteins, phase separation, granules, transcription Nasiha S. Ahmed et al. 1 Downloaded from rnajournal.cshlp.org on September 23, 2021 - Published by Cold Spring Harbor Laboratory Press ABSTRACT Ewing sarcoma is driven by fusion proteins containing a low complexity (LC) domain that is intrinsically disordered and a powerful transcriptional regulator. The most common fusion protein found in Ewing sarcoma, EWS-FLI1, takes its LC domain from the RNA-binding protein EWSR1 (Ewing Sarcoma RNA-binding protein 1) and a DNA-binding domain from the transcription factor FLI1 (Friend Leukemia Virus Integration 1). EWS- FLI1 can bind RNA polymerase II (RNA Pol II) and self-assemble through its low-complexity (LC) domain. The ability of RNA-binding proteins like EWSR1 to self-assemble or phase separate in cells has raised questions about the contribution of this process to EWS-FLI1 activity. We examined EWSR1 and EWS-FLI1 activity in Ewing sarcoma cells by siRNA-mediated knockdown and RNA-seq analysis. More transcripts were affected by the EWSR1 knockdown than expected and these included many EWS-FLI1 regulated genes.
    [Show full text]
  • BRE Plays an Essential Role in Preventing Replicative and DNA
    www.nature.com/scientificreports OPEN BRE plays an essential role in preventing replicative and DNA damage-induced premature Received: 08 December 2015 Accepted: 08 March 2016 senescence Published: 22 March 2016 Wenting Shi1, Mei Kuen Tang1, Yao Yao1, Chengcheng Tang1, Yiu Loon Chui2 & Kenneth Ka Ho Lee1 The BRE gene, alias BRCC45, produces a 44 kDa protein that is normally distributed in both cytoplasm and nucleus. In this study, we used adult fibroblasts isolated from wild-type (WT) and BRE knockout (BRE−/−) mice to investigate the functional role of BRE in DNA repair and cellular senescence. We compared WT with BRE−/− fibroblasts at different cell passages and observed that the mutant fibroblasts entered replicative senescence earlier than the WT fibroblasts. With the use of gamma irradiation to induce DNA damage in fibroblasts, the percentage of SA-β-Gal+ cells was significantly higher in BRE−/− fibroblasts compared with WT cells, suggesting that BRE is also associated with DNA damage-induced premature senescence. We also demonstrated that the gamma irradiation induced γ-H2AX foci, a DNA damage marker, persisted significantly longer in BRE−/− fibroblasts than in WT fibroblasts, confirming that the DNA repair process is impaired in the absence of BRE. In addition, the BRCA1-A complex recruitment and homologous recombination (HR)-dependent DNA repair process upon DNA damage were impaired in BRE−/− fibroblasts. Taken together, our results demonstrate a role for BRE in both replicative senescence and DNA damage-induced premature senescence. This can be attributed to BRE being required for BRCA1-A complex-driven HR DNA repair. Cellular senescence is an irreversible physiological process that accompanies abnormal and reduced metabolic activities.
    [Show full text]
  • The Role of Bach1, Bard1 and Topbp1 Genes in Familial Breast Cancer
    D 1019 OULU 2009 D 1019 UNIVERSITY OF OULU P.O.B. 7500 FI-90014 UNIVERSITY OF OULU FINLAND ACTA UNIVERSITATIS OULUENSIS ACTA UNIVERSITATIS OULUENSIS ACTA SERIES EDITORS DMEDICA Sanna-Maria Karppinen ASCIENTIAE RERUM NATURALIUM Sanna-MariaKarppinen Professor Mikko Siponen THE ROLE OF BACH1, BARD1 BHUMANIORA AND TOPBP1 GENES IN University Lecturer Elise Kärkkäinen CTECHNICA FAMILIAL BREAST CANCER Professor Hannu Heusala DMEDICA Professor Olli Vuolteenaho ESCIENTIAE RERUM SOCIALIUM Senior Researcher Eila Estola FSCRIPTA ACADEMICA Information officer Tiina Pistokoski GOECONOMICA University Lecturer Seppo Eriksson EDITOR IN CHIEF Professor Olli Vuolteenaho PUBLICATIONS EDITOR Publications Editor Kirsti Nurkkala FACULTY OF MEDICINE, INSTITUTE OF CLINICAL MEDICINE, DEPARTMENT OF CLINICAL GENETICS, ISBN 978-951-42-9158-6 (Paperback) UNIVERSITY OF OULU; ISBN 978-951-42-9159-3 (PDF) BIOCENTER OULU, ISSN 0355-3221 (Print) UNIVERSITY OF OULU ISSN 1796-2234 (Online) ACTA UNIVERSITATIS OULUENSIS D Medica 1019 SANNA-MARIA KARPPINEN THE ROLE OF BACH1, BARD1 AND TOPBP1 GENES IN FAMILIAL BREAST CANCER Academic dissertation to be presented with the assent of the Faculty of Medicine of the University of Oulu for public defence in Auditorium 5 of Oulu University Hospital, on 26 June 2009, at 12 noon OULUN YLIOPISTO, OULU 2009 Copyright © 2009 Acta Univ. Oul. D 1019, 2009 Supervised by Professor Robert Winqvist Reviewed by Docent Outi Monni Docent Minna Tanner ISBN 978-951-42-9158-6 (Paperback) ISBN 978-951-42-9159-3 (PDF) http://herkules.oulu.fi/isbn9789514291593/ ISSN 0355-3221 (Printed) ISSN 1796-2234 (Online) http://herkules.oulu.fi/issn03553221/ Cover design Raimo Ahonen OULU UNIVERSITY PRESS OULU 2009 Karppinen, Sanna-Maria, The role of BACH1, BARD1 and TOPBP1 genes in familial breast cancer Faculty of Medicine, Institute of Clinical Medicine, Department of Clinical Genetics, University of Oulu, P.O.
    [Show full text]